Questions?
Request a Medical Science Liaison (MSL)
Questions?
Request a Medical Science Liaison (MSL)
You are now leaving UptraviHCP.com
Clicking CONTINUE below will take you to the selected site, the content for which Johnson & Johnson is not responsible and to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every online service you visit.
Confirm that you wish to download the Veterans Affairs (VA) Patient Enrollment Form for UPTRAVI (selexipag)
The following form is intended for use with patients who are eligible for VA benefits only.
GRIPHON Is the Largest PAH Pivotal Trial With the Longest Endpoint Evaluation Period of Any Prostacyclin Pathway Therapy1-3
GRIPHON is the largest adult PAH pivotal trial, studied as monotherapy, dual therapy (ERA or PDE5i), and triple therapy (ERA + PDE5i)1,2
1156 Patients
UPTRAVI
(selexipag): n=574
Placebo:
n=582
Mean age:
48 years
Female:
80%
1.4 Years
(median duration of exposure to UPTRAVI)
Longest endpoint evaluation period of any prostacyclin pathway therapy
0.9 YearsÂ
Median time from PAH diagnosis in patients taking UPTRAVI
New England Journal of Medicine Clinical Trial Publication for GRIPHON
This article includes information that has not been approved by the Food and Drug Administration for UPTRAVI. Please see full Prescribing Information available on this website. Authors[s] of this article have received remuneration from Actelion Pharmaceuticals US, Inc., or its affiliates.
